Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 22, 2024
Deals

Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal

Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia
BioCentury | Mar 19, 2024
Deals

AZ deepens radiopharma commitment via $2B Fusion takeout

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Nov 30, 2022
Deals

Nov. 29 Quick Takes: Horizon names three possible buyers, discloses early M&A talks

Plus: TCG, Lux lead $96M A round for Cajal and updates from Sana, X4, Roche, Ribon and more
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

BioCentury’s roundup of preclinical news
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

Why Ipsen is revving up clinical-stage BD and adding a venture fund
BioCentury | Dec 4, 2014
Cover Story

GPCRs' grand plans

BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Neurology

Items per page:
1 - 9 of 9